Want to see WHWK full AI Analyst Report?
Top Page
Whitehawk Therapeutics
(NASDAQ:WHWK)
Select Model
Select Model
Rating:44Neutral
Price Target:
$3.00
▼(-38.40% Downside)
Action:Reiterated
Date:09/11/26
The score is held down primarily by very weak financial performance (zero TTM revenue, large ongoing losses, and substantial negative free cash flow). Technicals are also soft with the stock trading below key moving averages and weak momentum. Valuation offers limited support due to negative earnings and no dividend yield data, while corporate governance events are positive but secondary versus the fundamental cash burn and revenue profile.
Positive Factors
Minimal Leverage
An effectively debt-free balance sheet reduces fixed financial obligations and near-term refinancing pressure. This gives Whitehawk greater flexibility to direct available capital toward development activities, although it does not offset the company’s ongoing operating losses or cash consumption.
Negative Factors
Zero Revenue
A zero trailing-twelve-month revenue base indicates that Whitehawk has not yet established a dependable commercial or recurring revenue stream. This limits internal funding capacity, increases dependence on successful development milestones, and makes the business model vulnerable if commercialization is delayed.
Read all positive and negative factors
Positive Factors
Negative Factors
Minimal Leverage
An effectively debt-free balance sheet reduces fixed financial obligations and near-term refinancing pressure. This gives Whitehawk greater flexibility to direct available capital toward development activities, although it does not offset the company’s ongoing operating losses or cash consumption.
Read all positive factors
Whitehawk Therapeutics (WHWK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$188.13M
Dividend YieldN/A
Average Volume (3M)362.14K
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue Growth-100.00%
EPS Growth-1813.57%
CountryUS
Employees32
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.12
Shares Outstanding57,009,010
10 Day Avg. Volume320,177
30 Day Avg. Volume362,141
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.10
Price to Sales (P/S)20.96
P/FCF Ratio-1.53
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-37.93K
Enterprise Value/Ebitda-2.33
Forecast
1Y Price Target
$7.67Price Target Upside57.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.95
Revenue Forecast (FY)N/A
Whitehawk Therapeutics Business Overview & Revenue Model
Company Description
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. T...
Whitehawk Therapeutics Earnings Call Summary
Earnings Call Date:Mar 18, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Positive
The earnings call reflects a positive sentiment with significant strategic transformations, a promising pipeline of ADC therapies, and strong financial positioning. However, there are concerns about increased R&D expenses and net losses, which are common in early biotech transitions.Positive Updates
Transformation and Strategic Transactions
Whitehawk Therapeutics was launched from Aadi Biosciences, including in-licensing 3 ADCs from Wuxi Biologics, divestiture of FYARRO to Kaken Pharmaceuticals, and $100 million pipe financing, approved by stockholders.
Negative Updates
Increased R&D Expenses
Research and development expenses for Q4 increased to $14.3 million compared to $12.8 million in the prior year quarter, primarily due to in-process R&D expenses related to the acquired ADC programs.
Read all updates
Q4-2024 Updates
Positive
Negative
Transformation and Strategic Transactions
Whitehawk Therapeutics was launched from Aadi Biosciences, including in-licensing 3 ADCs from Wuxi Biologics, divestiture of FYARRO to Kaken Pharmaceuticals, and $100 million pipe financing, approved by stockholders.
Read all positive updates
Company Guidance
In the earnings call for the fourth quarter and full year 2024, Whitehawk Therapeutics provided guidance on their transformative shift from Aadi Biosciences to an ADC-focused company. The key metrics highlighted include a $100 million PIPE financing and the divestiture of FYARRO, which resulted in a financial position of $170 million to $180 million in cash and equivalents, expected to fund operations into 2028. The company reported FYARRO net product sales of $7.2 million for the fourth quarter, marking a 14% increase from the previous year, and $26 million for the full year, a 7% rise from 2023. Research and development expenses increased to $14.3 million for the quarter and $51 million for the year, primarily due to ADC program acquisitions. Whitehawk plans to file three Investigational New Drug (IND) applications within 15 months for their ADC candidates, targeting PTK7, MUC16, and SEZ6, with anticipated Phase 1 trials in several high-potential cancer indications.Whitehawk Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 7.14M | 25.98M | 24.35M | 15.22M | 1.12M |
| Gross Profit | -5.00K | 6.38M | -28.07M | -27.38M | -18.78M | -18.55M |
| EBITDA | -81.29M | -20.52M | -64.63M | -65.36M | -58.80M | -36.96M |
| Net Income | -79.83M | -20.60M | -63.69M | -65.77M | -60.51M | -110.09M |
Balance Sheet | ||||||
| Total Assets | 193.99M | 150.83M | 70.32M | 132.42M | 184.24M | 157.91M |
| Cash, Cash Equivalents and Short-Term Investments | 189.98M | 145.70M | 47.24M | 108.84M | 172.56M | 148.99M |
| Total Debt | 0.00 | 0.00 | 833.00K | 1.27M | 1.66M | 605.00K |
| Total Liabilities | 11.07M | 14.52M | 17.84M | 27.23M | 25.86M | 21.50M |
| Stockholders Equity | 182.93M | 136.31M | 52.48M | 105.19M | 158.38M | 136.41M |
Cash Flow | ||||||
| Free Cash Flow | -69.35M | -97.98M | -61.20M | -63.63M | -50.08M | -22.47M |
| Operating Cash Flow | -69.35M | -97.43M | -59.55M | -59.66M | -49.64M | -22.42M |
| Investing Cash Flow | -72.22M | 11.89M | 25.20M | 83.21M | -132.89M | 25.15M |
| Financing Cash Flow | 81.86M | 94.38M | 130.00K | 326.00K | 72.62M | 141.80M |
Whitehawk Therapeutics Technical Analysis
Negative
4.87
Price Trends
3.89
Negative
4.03
Negative
3.84
Negative
Market Momentum
-0.16
Negative
44.62
Neutral
86.83
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WHWK, the sentiment is Negative. The current price of 4.87 is above the 20-day moving average (MA) of 3.29, above the 50-day MA of 3.89, and above the 200-day MA of 3.84, indicating a neutral trend. The MACD of -0.16 indicates Negative momentum. The RSI at 44.62 is Neutral, neither overbought nor oversold. The STOCH value of 86.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WHWK.
Whitehawk Therapeutics Risk Analysis
Whitehawk Therapeutics disclosed 99 risk factors in its most recent earnings report. Whitehawk Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Whitehawk Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $175.96M | 1.00 | 72.96% | 6.79% | -100.00% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $188.13M | -2.95 | -53.89% | ― | -100.00% | -1813.57% | |
43 Neutral | $151.61M | -10.82 | -31.27% | ― | 1.32% | 59.94% | |
43 Neutral | $134.56M | -1.15 | -123.53% | ― | -100.00% | 52.43% | |
41 Neutral | $18.53M | -0.42 | -82.06% | ― | ― | -23.49% |
* Healthcare Sector Average
WHWK
Whitehawk Therapeutics
3.30
0.90
37.50%
MGNX
MacroGenics
2.38
0.72
43.37%
ORMP
Oramed Pharm
4.23
2.00
89.86%
SPRB
Spruce Biosciences
46.82
-63.28
-57.48%
CNTX
Context Therapeutics
0.20
-0.89
-81.56%
Whitehawk Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Whitehawk Therapeutics Adds Oncology Leader to Board
Positive
Sep 10, 2026
On September 9, 2026, Whitehawk Therapeutics, Inc. increased the size of its board of directors from nine to ten members and appointed Vijay Iyengar, M.D., as a Class III director with a term running through the 2029 annual meeting, subject to sta...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.